Bernhard-Nocht-Institut Fuer Tropenmedizin

At the Bernhard-Nocht-Institut Fuer Tropenmedizin in Hamburg, clinical research is focused on virus diseases, with studies centered on major infectious threats such as ebola virus infection, cytomegalovirus infection, chronic hepatitis B, and SARS-CoV-2. The trials are designed to evaluate vaccine protection, immune response, and overall safety in healthy volunteers and at-risk groups.

• Research on ebolavirus vaccine strategies to understand how long protection lasts and whether booster vaccination strengthens immunity.
• Studies of CMV vaccine candidates aimed at preventing primary infection and assessing safety and tolerability.
• Trials in hepatitis B exploring therapeutic vaccination approaches to improve immune control of chronic infection.

This work highlights the site’s role in advancing infectious disease prevention and vaccine research, with a strong emphasis on improving immune protection against serious viral illnesses.

The clinical trial program also reflects a broader focus on vaccine development and immunology, including studies that test new vaccine concepts for COVID-19, ebola, CMV, and hepatitis B. The main purpose is to determine whether these candidates are safe, trigger a strong immune response, and may offer better protection than existing approaches.

• Evaluation of a COVID-19 vaccine booster to see how well it enhances immune responses in healthy adults.
• Assessment of therapeutic hepatitis B vaccination for its ability to support immune control of chronic infection.
• Immunogenicity studies of ebolavirus vaccination to support prevention in people with potential occupational exposure.

These studies show a clear emphasis on translating laboratory expertise into practical clinical trials that can improve prevention and treatment options for viral diseases.